Skip to content

A randomized, open label, parallel-controlled trial for CO2 fraction laser combined with topical minoxidil in the treatment of androgenic alopecia

A randomized, open label, parallel-controlled trial for CO2 fraction laser combined with topical minoxidil in the treatment of androgenic alopecia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029451
Enrollment
Unknown
Registered
2020-02-02
Start date
2020-02-01
Completion date
Unknown
Last updated
2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

androgenic alopecia

Interventions

Group A:The hair loss area was treated by Co2 dot-matrix laser irradiation once, pulse energy 10 MJ, dot-matrix coverage 6.3% . After treatment, the hair was iced for 15 min, local water was avoided w
Group B:The hair loss area was treated by Co2 dot-matrix laser irradiation once, pulse energy 10 MJ, dot-matrix coverage 6.3% . After treatment, the hair was iced for 15 min, local water was avoided w
Group C:Local hair loss area for external use Minoxidil, once a day, for a year.

Sponsors

Shanghai tongji hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. The typical clinical manifestations were consistent with the diagnosis of AGA, and the degree of hair loss was consistent with the BASP classification of androgenic hair loss in male patients aged 20-60 years; 2. Generally good patients (no previous heart, systemic, scalp disease), the first 3 months of the study did not use any drugs that may affect the growth of hair (antihypertensive drugs, hormones, cytotoxic drugs, drugs with antiandrogenic effects, etc.); 3. Agree to participate in observation and follow-up, willing to accept the follow-up, can closely cooperate with the whole process of patients.

Exclusion criteria

Exclusion criteria: (1) Oral administration of finasteride within 18 months before the start of the test; (2) Use topical or systemic drugs that affect hair growth within 12 months; (3) History of hair transplantation; (4) Systemic or scalp diseases that may affect hair growth.

Design outcomes

Primary

MeasureTime frame
The same photographic method, according to P. Suchonwanit et AL's 7-point rating scale;

Secondary

MeasureTime frame
Severity of Alopecia Tool, SALT;Evaluation of hair regeneration rate;The hair thickness and hair density of Aga patients before and after treatment were measured by Dermatoscope, and the improvement was judged by comparing the median hair density and width (width) .;Evaluation of subjective satisfaction of patients;The quality of life (Qol) of patients was investigated by using the international dermatological quality of life questionnaire;

Countries

China

Contacts

Public ContactHuang Xin

Shanghai Tongji hospital

alida_huang@163.com+86 13524601485

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026